Sadayoshi Ito Selected Research

olmesartan

3/2016	Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure).
1/2015	Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial.
10/2014	Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.
12/2013	Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
5/2012	Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
4/2012	Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
8/2011	Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
3/2011	Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
11/2010	Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.
9/2006	Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sadayoshi Ito Research Topics

Disease

57	Hypertension (High Blood Pressure) 01/2023 - 09/2003
33	Diabetic Nephropathies (Diabetic Nephropathy) 01/2023 - 09/2003
31	Chronic Renal Insufficiency 01/2022 - 12/2007
21	Adenoma (Adenomas) 04/2024 - 07/2006
21	Albuminuria 07/2022 - 01/2005
19	Proteinuria 01/2023 - 12/2002
19	Hyperaldosteronism (Conn Syndrome) 01/2021 - 08/2006
18	Inflammation (Inflammations) 11/2021 - 12/2002
18	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 04/2003
18	Neoplasms (Cancer) 01/2020 - 08/2003
17	Type 2 Diabetes Mellitus (MODY) 10/2021 - 08/2003
16	Renal Insufficiency (Renal Failure) 11/2021 - 09/2004
14	Fibrosis (Cirrhosis) 02/2021 - 08/2005
12	Stroke (Strokes) 11/2018 - 03/2008
10	Insulin Resistance 01/2022 - 02/2002
10	Chronic Kidney Failure (Chronic Renal Failure) 01/2019 - 01/2003
10	Thyroiditis 01/2013 - 12/2002
9	Essential Hypertension 01/2022 - 04/2003
9	Atherosclerosis 12/2013 - 03/2002
9	Autoimmune Thyroiditis (Lymphomatous Thyroiditis) 01/2013 - 12/2002
8	Pre-Eclampsia (Preeclampsia) 06/2020 - 11/2016
8	Heart Failure 01/2017 - 08/2003
7	Diabetes Mellitus 01/2018 - 01/2003
6	Ischemia 05/2019 - 07/2011
6	Hyperplasia 10/2018 - 02/2014
6	Renal Artery Obstruction (Renal Artery Stenosis) 11/2010 - 03/2005
5	Kidney Diseases (Kidney Disease) 11/2021 - 10/2008
5	Body Weight (Weight, Body) 10/2020 - 01/2010
5	Obesity 10/2020 - 12/2003
5	Adrenocortical Adenoma (Disease, Conn's) 01/2020 - 08/2003
4	Wounds and Injuries (Trauma) 10/2019 - 02/2009
4	Acute Kidney Injury (Acute Renal Failure) 05/2019 - 01/2003
4	Mitochondrial Diseases (Mitochondrial Disease) 06/2017 - 01/2015
3	Cerebral Hemorrhage 01/2022 - 01/2018
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2021 - 12/2003
3	Atrophy 01/2021 - 08/2003
3	Hyperuricemia 01/2021 - 12/2018
3	Fetal Growth Retardation (Intrauterine Growth Retardation) 01/2020 - 11/2016
3	Hypoxia (Hypoxemia) 01/2020 - 02/2016
3	Hypotension (Low Blood Pressure) 10/2019 - 01/2014
3	Infections 11/2018 - 04/2000
3	Autoimmune Diseases (Autoimmune Disease) 11/2017 - 11/2004

Drug/Important Bio-Agent (IBA)

34	AldosteroneIBA 04/2024 - 08/2003
24	CreatinineIBA 01/2023 - 10/2003
22	Antihypertensive Agents (Antihypertensives)IBA 01/2023 - 06/2003
18	AlbuminsIBA 01/2023 - 02/2004
16	Angiotensin Receptor AntagonistsIBA 01/2023 - 10/2003
14	esaxerenoneIBA 01/2023 - 01/2019
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2000
13	Angiotensin IIIBA 08/2012 - 08/2005
11	Glucose (Dextrose)FDA LinkGeneric 07/2022 - 12/2003
11	ReninIBA 02/2021 - 10/2003
10	Uremic ToxinsIBA 11/2021 - 12/2009
10	olmesartanIBA 03/2016 - 09/2006
10	Losartan (Cozaar)FDA LinkGeneric 08/2012 - 06/2003
9	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2022 - 01/2019
9	Cytochrome P-450 CYP11B2 (CYP11B2)IBA 01/2020 - 02/2011
9	Messenger RNA (mRNA)IBA 04/2019 - 12/2002
8	Adenine FDA LinkGeneric 11/2021 - 08/2015
8	SaltsIBA 01/2020 - 02/2009
8	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 12/2019 - 04/2003
7	Uric Acid (Urate)IBA 01/2021 - 06/2010
6	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2023 - 04/2003
6	Niacinamide (Nicotinamide)FDA LinkGeneric 11/2021 - 11/2016
6	SteroidsIBA 06/2019 - 03/2002
6	EnzymesIBA 01/2019 - 02/2004
6	IodidesIBA 01/2013 - 12/2002
5	Adenosine Triphosphate (ATP)IBA 01/2020 - 01/2015
5	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2010
5	Pyruvaldehyde (Methylglyoxal)IBA 01/2018 - 10/2008
5	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 12/2013 - 08/2011
4	PotassiumIBA 01/2023 - 01/2008
4	Blood Glucose (Blood Sugar)IBA 12/2021 - 09/2008
4	Tolvaptan FDA Link 04/2019 - 01/2013
4	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2017 - 06/2009
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 11/2004
4	DiureticsIBA 01/2017 - 10/2014
4	benidipineIBA 12/2013 - 08/2011
3	SodiumIBA 07/2022 - 01/2003
3	HydrogenIBA 01/2022 - 09/2010
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 05/2006
3	AST 120IBA 01/2020 - 11/2012
3	Insulin (Novolin)FDA Link 11/2019 - 12/2003
3	CytokinesIBA 10/2019 - 01/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2019 - 01/2018
3	Factor Xa (Coagulation Factor Xa)IBA 01/2019 - 01/2016
3	18-oxocortisolIBA 01/2019 - 08/2011
3	Renin InhibitorsIBA 01/2019 - 11/2011
3	Erythropoietin FDA Link 01/2019 - 10/2013
3	PAR-2 ReceptorIBA 01/2019 - 01/2016
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 09/2011
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 01/2006
3	Mitochondrial DNA (mtDNA)IBA 01/2018 - 01/2015
3	Hemoglobins (Hemoglobin)IBA 12/2017 - 12/2013

Therapy/Procedure

46	Therapeutics 07/2022 - 03/2002
6	Renal Replacement Therapy (Therapies, Renal Replacement) 09/2020 - 10/2015
6	Renal Dialysis (Hemodialysis) 09/2020 - 09/2004
5	Peritoneal Dialysis 11/2018 - 01/2016
4	Adrenalectomy 03/2016 - 07/2011
4	Glycemic Control 01/2013 - 01/2010